Jonah Wiseman Perlmutter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jonah Wiseman Perlmutter has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Romy Levy
Temerty Faculty of Medicine, University of Toronto, ON, Canada
4 shared publications - Siddhartha Sood
Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada
4 shared publications Abrahim Abduelmula
3 shared publicationsJensen Yeung
3 shared publications- Michal Moshkovich
Temerty Faculty of Medicine, University of Toronto, ON, Canada
3 shared publications Romy Levy
Temerty Faculty of Medicine University of Toronto Toronto Ontario Canada
3 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Elsevier in JAAD Reviews
- Vol. 10, 174-176
Targeted therapies in the treatment of oral lichen planus: A systematic review
- 27 October 2026
- Published by Elsevier in JAAD Reviews
- Vol. 10, 174-176
Open AccessTargeted therapies in the treatment of oral lichen planus: A systematic review
- Open Access
- 29 September 2026
- Published by SAGE Publications in Plastic Surgery
Artificial Intelligence in the Management of Facial Palsy: A Narrative Review Across the Care Continuum
Introduction: Facial paralysis produces substantial functional and psychosocial impairment which facial reanimation surgery seeks to mitigate by restoring facial movement and improving symmetry. However, despite technical advances in nerve- and muscle-based reconstruction, perioperative evaluation and outcome assessment remain largely subjective and variably reproducible. Artificial intelligence (AI) and computer vision have emerged as tools to provide objective, scalable assessment across the facial reanimation care pathway. Methods: MEDLINE, Embase, and the Cochrane Library were searched extensively to identify studies evaluating AI applications relevant to facial reanimation surgery. Included studies were screened by three independent reviewers and mapped to stages of perioperative care using an evidence-mapping framework. Results: Thirteen studies met inclusion criteria and were distributed across multiple stages of care. Evidence was most concentrated in diagnosis and severity assessment and in postoperative follow-up, where AI systems automated facial grading scales, quantified asymmetry, and extracted dynamic motion features from photographs and video. Several machine learning and deep learning models demonstrated high diagnostic accuracy and strong correlations with clinician-assigned scores, often exceeding inter-rater reliability of traditional grading systems. Fewer studies addressed prognostic modeling, preoperative planning, or rehabilitation, though emerging applications included outcome prediction, three-dimensional symmetry analysis, and AI-assisted evaluation of spontaneous emotional expression after reanimation. Conclusion: AI applications in facial paralysis care are most mature in assessment and outcome measurement, where they offer improved objectivity and reproducibility. However, broader clinical integration will require larger, diverse datasets, prospective validation, and alignment with ethical and regulatory standards to demonstrate meaningful patient centered benefit.
- 29 September 2026
- Published by SAGE Publications in Plastic Surgery
Open AccessArtificial Intelligence in the Management of Facial Palsy: A Narrative Review Across the Care Continuum
Introduction: Facial paralysis produces substantial functional and psychosocial impairment which facial reanimation surgery seeks to mitigate by restoring facial movement and improving symmetry. However, despite technical advances in nerve- and muscle-based reconstruction, perioperative evaluation and outcome assessment remain largely subjective and variably reproducible. Artificial intelligence (AI) and computer vision have emerged as tools to provide objective, scalable assessment across the facial reanimation care pathway. Methods: MEDLINE, Embase, and the Cochrane Library were searched extensively to identify studies evaluating AI applications relevant to facial reanimation surgery. Included studies were screened by three independent reviewers and mapped to stages of perioperative care using an evidence-mapping framework. Results: Thirteen studies met inclusion criteria and were distributed across multiple stages of care. Evidence was most concentrated in diagnosis and severity assessment and in postoperative follow-up, where AI systems automated facial grading scales, quantified asymmetry, and extracted dynamic motion features from photographs and video. Several machine learning and deep learning models demonstrated high diagnostic accuracy and strong correlations with clinician-assigned scores, often exceeding inter-rater reliability of traditional grading systems. Fewer studies addressed prognostic modeling, preoperative planning, or rehabilitation, though emerging applications included outcome prediction, three-dimensional symmetry analysis, and AI-assisted evaluation of spontaneous emotional expression after reanimation. Conclusion: AI applications in facial paralysis care are most mature in assessment and outcome measurement, where they offer improved objectivity and reproducibility. However, broader clinical integration will require larger, diverse datasets, prospective validation, and alignment with ethical and regulatory standards to demonstrate meaningful patient centered benefit.
- Open Access
- 15 September 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Rosacea Presentation Across Race and Ethnicity: A Systematic Review
- 15 September 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Open AccessRosacea Presentation Across Race and Ethnicity: A Systematic Review
- Open Access
- 16 July 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (11) , 2089-2092
Long-term remission of severe psoriasis following CD19-directed chimeric antigen receptor T-cell therapy for follicular lymphoma
Psoriasis is a chronic, immune-mediated inflammatory disease in which durable, treatment-free remission is rarely achieved despite highly effective biologic therapies. We report a 60-year-old woman with a 49-year history of severe plaque psoriasis who developed complete and sustained disease clearance following autologous CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for follicular lymphoma. Psoriasis resolved within 4 weeks of CD19 CAR-T therapy, and the patient has remained in remission for 5 years without any psoriasis-directed treatment. This observation, together with emerging reports, suggests that deep tissue depletion of B-lymphoid lineage cells in psoriasis may induce long-term disease modification. Mechanistically, CD19 CAR-T therapy targets a broader spectrum of B-cell populations than anti-CD20 approaches, potentially disrupting pathogenic B–T-cell interactions and autoreactive immune circuits. These findings challenge the prevailing T-cell-centric paradigm of psoriasis and support exploration of B-cell-directed, immune reset strategies as a route towards durable remission or cure.
- 16 July 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (11) , 2089-2092
Open AccessLong-term remission of severe psoriasis following CD19-directed chimeric antigen receptor T-cell therapy for follicular lymphoma
Psoriasis is a chronic, immune-mediated inflammatory disease in which durable, treatment-free remission is rarely achieved despite highly effective biologic therapies. We report a 60-year-old woman with a 49-year history of severe plaque psoriasis who developed complete and sustained disease clearance following autologous CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for follicular lymphoma. Psoriasis resolved within 4 weeks of CD19 CAR-T therapy, and the patient has remained in remission for 5 years without any psoriasis-directed treatment. This observation, together with emerging reports, suggests that deep tissue depletion of B-lymphoid lineage cells in psoriasis may induce long-term disease modification. Mechanistically, CD19 CAR-T therapy targets a broader spectrum of B-cell populations than anti-CD20 approaches, potentially disrupting pathogenic B–T-cell interactions and autoreactive immune circuits. These findings challenge the prevailing T-cell-centric paradigm of psoriasis and support exploration of B-cell-directed, immune reset strategies as a route towards durable remission or cure.
- Open Access
- 10 April 2026
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (4) , 856-861
Impact of Pediatric Psoriasis on Child and Caregiver Health‐Related Quality of Life: A Systematic Review and Meta‐Analysis
Background: Pediatric psoriasis is a chronic inflammatory skin disease that affects both physical and psychosocial well‐being. The impact of the disease extends beyond the patient, significantly affecting caregivers' emotional and functional quality of life. Objectives: This systematic review and meta‐analysis aimed to evaluate the health‐related quality of life (HrQOL) burden of pediatric psoriasis on children and their caregivers. The study also sought to identify clinical and child‐related factors associated with increased impairment in HrQOL. Methods: A systematic search of MEDLINE and Embase databases was conducted according to PRISMA guidelines. Studies included children under 18 years of age with a diagnosis of psoriasis and/or their caregivers, reporting outcomes using validated HrQOL measures. Two reviewers independently screened studies, extracted data, and assessed quality using the Mixed Methods Appraisal Tool. Where appropriate, correlation coefficients were pooled using random‐effects meta‐analysis after Fisher's Z ‐transformation. Results: Twenty‐one studies were included, encompassing 1038 children and 1161 caregivers. The most commonly used instruments were the Children's Dermatology Life Quality Index (CDLQI) and Family Dermatology Life Quality Index (FDLQI). Across studies, 84.8% of children and 96.1% of caregivers experienced some degree of HrQOL impairment. Meta‐analysis revealed a moderate positive correlation between child disease severity (PASI scores) and caregiver HrQOL burden ( r = 0.463), while no significant correlation was found with child age or disease duration. Amongst children, HrQOL was most affected in the domains of symptoms, leisure, and treatment‐related concerns. Conclusions: Pediatric psoriasis exerts a substantial impact on both child and caregiver quality of life, with greater burden associated with more severe disease. These findings highlight the need for early intervention and psychosocial support targeting families. Clinicians should consider the broader family context when managing pediatric psoriasis and prioritize counseling during disease flares to mitigate emotional and functional strain.
- 10 April 2026
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (4) , 856-861
Open AccessImpact of Pediatric Psoriasis on Child and Caregiver Health‐Related Quality of Life: A Systematic Review and Meta‐Analysis
Background: Pediatric psoriasis is a chronic inflammatory skin disease that affects both physical and psychosocial well‐being. The impact of the disease extends beyond the patient, significantly affecting caregivers' emotional and functional quality of life. Objectives: This systematic review and meta‐analysis aimed to evaluate the health‐related quality of life (HrQOL) burden of pediatric psoriasis on children and their caregivers. The study also sought to identify clinical and child‐related factors associated with increased impairment in HrQOL. Methods: A systematic search of MEDLINE and Embase databases was conducted according to PRISMA guidelines. Studies included children under 18 years of age with a diagnosis of psoriasis and/or their caregivers, reporting outcomes using validated HrQOL measures. Two reviewers independently screened studies, extracted data, and assessed quality using the Mixed Methods Appraisal Tool. Where appropriate, correlation coefficients were pooled using random‐effects meta‐analysis after Fisher's Z ‐transformation. Results: Twenty‐one studies were included, encompassing 1038 children and 1161 caregivers. The most commonly used instruments were the Children's Dermatology Life Quality Index (CDLQI) and Family Dermatology Life Quality Index (FDLQI). Across studies, 84.8% of children and 96.1% of caregivers experienced some degree of HrQOL impairment. Meta‐analysis revealed a moderate positive correlation between child disease severity (PASI scores) and caregiver HrQOL burden ( r = 0.463), while no significant correlation was found with child age or disease duration. Amongst children, HrQOL was most affected in the domains of symptoms, leisure, and treatment‐related concerns. Conclusions: Pediatric psoriasis exerts a substantial impact on both child and caregiver quality of life, with greater burden associated with more severe disease. These findings highlight the need for early intervention and psychosocial support targeting families. Clinicians should consider the broader family context when managing pediatric psoriasis and prioritize counseling during disease flares to mitigate emotional and functional strain.
- Open Access
- 19 January 2026
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Treatments for actinic prurigo: A case report with upadacitinib and systematic review
This study aims to evaluate treatments for actinic prurigo, a chronic, photosensitive dermatosis disproportionately affecting Indigenous populations. We present the case of a 49-year-old Indigenous woman with refractory actinic prurigo successfully managed with upadacitinib, a Janus kinase inhibitor. After inadequate responses to photoprotection and topical corticosteroids, the patient demonstrated substantial clinical improvement with systemic upadacitinib therapy, achieving marked symptom reduction and improved quality of life. A systematic review including 334 actinic prurigo patients from 38 studies found the highest complete resolution rates with Janus kinase inhibitors (100%), hydroxychloroquine (100%), and topical tacrolimus (100%). Treatment recurrence was common with thalidomide (34%), highlighting limitations of traditional therapies. Janus kinase inhibitors, targeting cytokine-driven inflammation, appear particularly promising. Although further large-scale studies are needed, our findings suggest Janus kinase inhibitors such as upadacitinib offer effective and safe treatment alternatives for refractory actinic prurigo, significantly enhancing patient outcomes and quality of life.
- 19 January 2026
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Open AccessTreatments for actinic prurigo: A case report with upadacitinib and systematic review
This study aims to evaluate treatments for actinic prurigo, a chronic, photosensitive dermatosis disproportionately affecting Indigenous populations. We present the case of a 49-year-old Indigenous woman with refractory actinic prurigo successfully managed with upadacitinib, a Janus kinase inhibitor. After inadequate responses to photoprotection and topical corticosteroids, the patient demonstrated substantial clinical improvement with systemic upadacitinib therapy, achieving marked symptom reduction and improved quality of life. A systematic review including 334 actinic prurigo patients from 38 studies found the highest complete resolution rates with Janus kinase inhibitors (100%), hydroxychloroquine (100%), and topical tacrolimus (100%). Treatment recurrence was common with thalidomide (34%), highlighting limitations of traditional therapies. Janus kinase inhibitors, targeting cytokine-driven inflammation, appear particularly promising. Although further large-scale studies are needed, our findings suggest Janus kinase inhibitors such as upadacitinib offer effective and safe treatment alternatives for refractory actinic prurigo, significantly enhancing patient outcomes and quality of life.